Antisense Oligonucleotides Inhibit FOXP3 Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to effectively target and inhibit FOXP3 expression, which is crucial for regulating immunosuppressive Tregs in cancer, as FOXP3 lacks specific surface markers or signaling proteins for targeting with conventional biologics or small molecules.
Innovation Solution
Development of potent and tolerable compounds and compositions, such as modified oligonucleotides, that specifically inhibit FOXP3 expression in Tregs, utilizing antisense mechanisms to target FOXP3 nucleic acids and modulate its activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional biologics or small molecules are used to target FOXP3, then targeting capability is limited, but the lack of specific surface markers or signaling proteins prevents effective inhibition of FOXP3 expression
Solution Approach 1:
The patent uses antisense oligonucleotides as intermediary molecules that bind to FOXP3 mRNA through complementary base pairing, enabling specific targeting of FOXP3 expression without requiring surface markers or signaling proteins on Tregs. This mediator approach resolves the contradiction by providing a direct molecular recognition mechanism.
Solution Approach 2:
The patent replaces conventional biologic targeting mechanisms (which rely on surface markers and signaling proteins) with a nucleic acid-based antisense mechanism. This substitution enables specific inhibition of FOXP3 at the transcriptional level, overcoming the limitation of lacking surface targets.
2Reliability
If FOXP3 expression is inhibited in Tregs, then anti-tumor immunity is enhanced, but the absence of unique surface markers complicates selective targeting
Solution Approach 1:
The antisense oligonucleotide serves as a mediator that specifically recognizes and binds to FOXP3 mRNA sequences, enabling selective inhibition of FOXP3 expression in Tregs without affecting other cell types. This provides a mechanism for detecting and measuring FOXP3 expression levels through the binding interaction.
Solution Approach 2:
The patent applies local quality by designing antisense oligonucleotides with specific sequence complementarity to FOXP3 mRNA, enabling targeted inhibition at the molecular level within Tregs while leaving other cells unaffected. This localized molecular recognition solves the selective targeting problem.
3Reliability
If modified oligonucleotides are used to inhibit FOXP3 expression, then FOXP3 inhibition efficacy is improved, but the complexity of compound design and synthesis increases
Solution Approach 1:
The patent modifies oligonucleotide parameters including sugar modifications (2'-O-methoxyethyl, locked nucleic acids), phosphate backbone modifications (phosphorothioates), and nucleobase modifications to enhance FOXP3 inhibition efficacy, cellular uptake, and stability while reducing immunogenicity. These parameter changes balance efficacy with manufacturability.
Solution Approach 2:
The patent creates composite oligonucleotide structures combining multiple modified components (modified sugars, phosphorothioate linkages, nucleobase modifications) within a single molecule. This composite approach achieves superior FOXP3 inhibition while utilizing established synthetic methodologies for each component.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds effectively inhibit FOXP3 expression, potentially enhancing anti-tumor immunity by reducing immunosuppression, thereby slowing cancer progression and improving treatment outcomes for cancers associated with immunosuppressive microenvironments.
Implementation Method 1
utilizing antisense mechanisms to target FOXP3 nucleic acids and modulate its activity
Data Source
AI summary
The present embodiments provide methods, compounds, and compositions useful for inhibiting FOXP3 expression, which may be useful for treating, preventing, or ameliorating cancer.